

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
January 11, 2023

---

**CLEARPOINT NEURO, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-34822**  
(Commission  
File Number)

**58-2394628**  
(I.R.S. Employer  
Identification Number)

**120 S. Sierra Ave., Suite 100**  
**Solana Beach, CA 92075**  
(Address of principal executive offices, zip code)

**(888) 287-9109**  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value per share	CLPT	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 2.02. Results of Operations and Financial Condition.**

On January 11, 2023, ClearPoint Neuro, Inc. (the “Company”) issued a press release announcing its preliminary, unaudited financial results for the fourth fiscal quarter ended December 31, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 7.01. Regulation FD Disclosure.**

On January 11, 2023, the Company posted an updated investor presentation to its website at <http://ir.stockpr.com/clearpointneuro/investor-presentations>. A copy of the investor presentation is being furnished herewith as Exhibit 99.2. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit 99.1	<a href="#">Press Release dated January 11, 2023</a>
Exhibit 99.2	<a href="#">Investor Presentation dated January 11, 2023</a>
Exhibit 104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 11, 2023

**CLEARPOINT NEURO, INC.**

By: /s/ Danilo D'Alessandro  
Danilo D'Alessandro  
Chief Financial Officer



## **ClearPoint Neuro Reports Fourth Quarter and Full Year 2022 Preliminary Revenue Results and Guidance for Full Year 2023 Revenue**

SOLANA BEACH, CA, January 11, 2023 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced preliminary, unaudited financial results for its fourth quarter and full year ended December 31, 2022.

### **Fourth Quarter 2022 Preliminary Unaudited Financial Highlights**

- Preliminary unaudited revenue of \$5.2 million, a 21% year-over-year increase;
- Increased biologics and drug delivery revenue to \$2.3 million, a 37% year-over-year increase;
- Increased functional neurosurgery products and services to \$2.3 million, a 7% year-over-year increase;
- Cash burn of approximately \$3.0 million in the fourth quarter. The Company had approximately \$37.5 million in cash, cash equivalents, and short-term investments at December 31, 2022.

### **Full Year 2022 Preliminary Unaudited Financial Highlights**

- Achieved preliminary unaudited record revenue of \$20.6 million, a 26% year-over-year increase, versus most recent guidance of \$21.0 - \$22.0 million;
- Increased biologics and drug delivery revenue to \$9.1 million, a 34% year-over-year increase;
- Increased functional neurosurgery products and services revenue to \$9.1 million, a 13% year-over-year increase;
- Added multiple new biologics and drug delivery partners in the year to bring the total to more than 50 partners.

### **Business Outlook and Planned Value Creating Milestones**

- The Company estimates revenue in 2023 to be between \$25.0 million and \$27.0 million, representing growth between 22% and 31%;
  - Submission to the FDA of a Biologics License Application (BLA) by PTC Therapeutics for Upstaza™, using the ClearPoint SmartFlow® Cannula for minimally invasive infusion of the gene therapy;
  - Initiation of multiple pharmaceutical partner clinical trials globally;
  - Expansion of the installed base to approximately 10 additional centers worldwide;
  - Revenue growth from international customers driven by 8 active centers installed in the E.U. and U.K.;
  - Commercialization of the ClearPoint PRISM™ Neuro Laser Therapy System and expansion into limited market release centers;
  - Completion of Phase 1 safety study in Lund, Sweden, for the use of PRISM™ for brain lesions;
  - Up to 8 FDA submissions for new hardware and software products in our portfolio;
  - Production of first devices at our new expanded manufacturing facility in California.
-

“Our team made tremendous progress toward our four-pillar growth strategy in 2022 and finished the year with approximately 26% growth in revenue, driven by the 34% revenue growth in our biologics and drug delivery business, and 11 new centers installed worldwide,” commented Joe Burnett, President and CEO of ClearPoint Neuro. “While recognized revenue in the fourth quarter was below our expectations based on timing and delivery for certain products and services, our backlog of received purchase orders grew to the highest level in our history setting us up for a strong 2023. We are forecasting revenue for 2023 in the range of \$25.0 million to \$27.0 million, representing growth of between 22% and 31% percent. Our team has done a great job managing our cash position in the past year by pausing less crucial programs while continuing to invest in our supply chain to ensure product availability to hospitals and our pharmaceutical partners. As a result, our cash burn in the fourth quarter was approximately \$3.0 million, which was the lowest in several quarters, bringing our current cash, cash equivalents, and short-term investments balance at year end to approximately \$37.5 million.”

The preliminary unaudited financial results described in the press release are estimates only and subject to revision until we report our full financial results for the fourth quarter and full year 2022 during our upcoming earnings announcement.

### **About ClearPoint Neuro**

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in more than 65 sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with more than 50 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 5,000 cases have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners. For more information, please visit [www.clearpointneuro.com](http://www.clearpointneuro.com).

### **Forward-Looking Statements**

Statements in this press release covering preliminary financial results for completed periods and expected results in future periods, and statements concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company’s future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company’s products and services, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company’s actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic, global instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company’s ClearPoint Neuro Navigation System and other new products offered by the Company; the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System and other new products offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of our products and services in their delivery of therapies; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and the Company’s Quarterly Report on Form 10-Q for the three months ended September 30, 2022, both of which have been filed with the Securities and Exchange Commission, and the Company’s Annual Report on Form 10-

---

K for the year ended December 31, 2022, which the Company intends to file with the Securities and Exchange Commission on or before March 31, 2023.

**Contact:**

Danilo D'Alessandro, Chief Financial Officer

(949) 900-6833

[info@clearpointneuro.com](mailto:info@clearpointneuro.com)

Caroline Corner, Investor Relations

[ir@clearpointneuro.com](mailto:ir@clearpointneuro.com)



CLEARPOINT®  
NEURO

WHEN YOUR PATH IS UNCLEAR,  
WE POINT THE WAY.™

Nasdaq: CLPT

January 2023



---


*Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, preliminary financial results for completed periods and expected results in future periods, the size of total addressable markets or the market opportunity for the Company's products and services, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic, global instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company's ClearPoint Neuro Navigation System and other new products offered by the Company; the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System and other new products offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of our products and services in their delivery of therapies; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2022, both of which have been filed with the Securities and Exchange Commission, and the Company's Annual Report on Form 10-K for the year ended December 31, 2022, which the Company intends to file with the Securities and Exchange Commission on or before March 31, 2023.*



# ClearPoint Neuro: Two Opportunities, One Platform



- A Common Installed Base Platform and Clinical Specialist Support team
- 35 Active Indications totaling more than 1 million patients diagnosed annually
- A \$12B+ Potential Total Addressable Market



**1 A Biologics & Drug Delivery Enabling Company with;**

- A unique portfolio of Navigation Tools, Infusion Cannulas, Pre-Clinical and Clinical Services
- More than 50 active pharma/biotech, academic and contract research organization partners

**2 A Neuro Navigation and Device Company with;**

- A growing portfolio of Navigation, Therapy and Access Devices supporting DBS, Laser Ablation, Biopsy and Brain Computer Interface implantation
- An expanding global installed base of more than 65 centers

Our Company

# ClearPoint Neuro: A Proven Platform

Key Products: FDA CE Marked Platforms

HEADQUARTERS

Solana Beach, CA

MANUFACTURING

Irvine, CA

EUROPEAN HEADQUARTERS

London, UK

2022 REVENUE

\$20.6m<sup>(A)</sup>

CASH & SHORT-TERM INVESTMENTS

\$37.5m<sup>(A)</sup>

PATENTS ISSUED

75+<sup>(B)</sup>

GROSS MARGIN

69%<sup>(A,C)</sup>

EMPLOYEES

100+



(A) Estimated and subject to revision. Preliminary, unaudited financial result for full year ended Dec. 31, 2022

(B) Including owned and licensed patents

(C) For the September 2022 Trailing Twelve Months (TTM)

# Limitations of Traditional Stereotactic Neurosurgery

## Lack of Real-Time Image Guidance

### PRIMARY CHALLENGE

For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head

MRI is the best imaging tool for the brain

Large, metallic frames are not MRI compatible





*Big Iron companies like Siemens and Philips are innovating to make interoperative MRI scanners more accessible*



Our Platform – Procedure Overview


# The ClearPoint® Neuro Navigation System



Leverage live MR Imaging to Decide, Guide, Treat and Confirm with sub-millimetric accuracy.


Our Platform

### SmartFrame® XG



SmartFrame XG Trajectory Tower  
with ClearPoint 2.1 Software

### SmartFrame Array™





SmartFrame Array Tower  
with "virtual array" Software and next generation robotic  
system with increased automation and enabling software\*

ClearPoint plans to translate more than 10 years of experience  
and over 5,000 cases performed in the complex MRI suite into  
unique and competitive products for the Operating Room

## Our Platform

# The ClearPoint 'Maestro' Brain Model\* Licensed and Jointly Developed with Philips

1. Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects.
2. Fast and capable of peri-procedural imaging without CPU acceleration.
3. This model is the basis for future navigation tools, for both the MRI suite and OR, across Biologics & Drug Delivery, DBS Navigation, Brain Computer Interface, Laser Ablation and more.



Broad and Growing User Base of Leading Neurosurgery Centers

# 65+ Centers in the US, Canada and EU... and Growing Globally

UC San Francisco  
Stanford University  
Lucile Packard Children's Hospital  
Benioff Children's Hospital  
San Francisco VA  
USC Keck Hospital  
UC San Diego  
Mayo Clinic in Arizona  
University of Colorado  
University of Utah  
Cook Children's Hospital  
Texas Children's Hospital  
MD Anderson Cancer Center  
Houston Methodist Hospital  
Univ. Kansas Medical Center  
Dallas Presbyterian Hospital  
Cincinnati Jewish  
Children's National  
Banner Health Tucson  
Ohio State University  
University of Oklahoma Medical Center  
Methodist Hospital San Antonio  
Barnes-Jewish Hospital  
Froedtert Hospital

University of Wisconsin  
University of Michigan  
University of Minnesota  
Cleveland Clinic  
Northwestern Central DuPage  
Nationwide Children's  
Le Bonheur  
INOVA Fairfax  
Cincinnati Children's Hospital

Charles River Labs – Laval  
Charles River Labs – Mattawan  
Children's Mercy Hospital  
CHOA Scottish Rite  
Carilion Clinic  
UPMC  
Hos. Univ. of Pennsylvania  
University of Alabama at Birmingham  
Children's Hospital of Alabama

Rigshospitalet (Copenhagen, Denmark)  
Mazowiecki Szpital Bródnowski (Warsaw, Poland)  
Hôpital Fondation Rothschild (Paris, France)  
Skånes Universitetssjukhus Lund (Lund, Sweden)  
University Hospital of Wales (United Kingdom)  
Universitätsklinikum Düsseldorf (Düsseldorf, Germany)  
Universitätsklinikum Freiburg (Freiburg, Germany)  
Policlinico Umberto I (Rome, Italy)

Emory University  
Mt. Sinai West  
Yale University  
Weill Cornell  
Johns Hopkins University  
Boston Children's Hospital  
Massachusetts General Hospital  
Brigham & Women's  
Duke University  
National Institutes of Health  
Memorial Sloan-Kettering  
Dartmouth-Hitchcock  
Beth Israel Deaconess  
Children's Hospital of Philadelphia  
Hackensack Univ. Med. Center  
University of Virginia  
Tampa General Hospital  
Mayo Clinic in Florida

100+  
Centers  
Expected  
by 2025

# Our MRI-guided therapy platform is currently being used to...

CLPT PLATFORM RUNS ON ALL MAJOR SCANNERS

DELIVER BIOLOGICS AND DRUGS

IMPLANT NEURO STIMULATION LEADS

LASER THERAPY

SIEMENS



PHILIPS



uniQure

charles river



LYSOGENE

Medtronic



Boston Scientific



Medtronic VISUALASE

MONTERIS MEDICAL




... More than 50 total commercial and academic partners



2014 - 2023

# Growth in Product and Service Revenue



# ClearPoint Neuro Market Opportunity – United States

~\$12B+ Opportunity: Empowering Multiple Treatment Options for 35+ Indications\*

**Pillar 4:  
Global Expansion**  
~2 X U.S. Revenue

Indication	Patient Population	Annual Incidence	Pillar 1: Drug/Cell Delivery	Pillar 2: DBS & BCI	Pillar 3: Laser Therapy	Incremental Revenue from Annual Incidence
Parkinson's Disease	1,000,000 <sup>1</sup>	60,000 <sup>1</sup>	○ ○	●	●	\$270 M - \$1.35 B
Drug Resistant Epilepsy	1,000,000 <sup>2</sup>	11,000 <sup>3</sup>	○ ○	●	●	\$49.5 M - \$198 M
Refractory Essential Tremor	3,500,000 <sup>4</sup>	60,000 <sup>5</sup>		●	○	\$180 M - \$1.08 B
Brain Tumors (n=3) <sup>6</sup>	35,000 <sup>7,8</sup>	13,300 <sup>7,8</sup>	○ ○		●	\$33.3 M - \$300 M
Severe Obsessive-Compulsive Disorder	500,000 <sup>9,10</sup>	10,000 <sup>9,10</sup>		●		\$45 M - \$75 M
Dystonia	250,000 <sup>11</sup>	8,000 <sup>12</sup>		●		\$36 M - \$60 M
Rare Genetic/Lysosomal (n=7) <sup>13</sup>	36,500 <sup>14-18</sup>	3,000 <sup>14,19,20</sup>	○ ○			\$13.5 M - \$67.5 M
Paralysis / Spinal Cord (n=15) <sup>21,22</sup>	331,000 <sup>22-24</sup>	17,900 <sup>23</sup>	○ ○	○		\$80.6 M - \$403 M
Huntington's Disease	30,000 <sup>25</sup>	4,000 <sup>25</sup>	○ ○	○		\$18 M - \$90 M
Auditory Nerve Implant	1,867,000 <sup>26,27</sup>	7,000 <sup>26,27</sup>		○		\$31.5 M - \$63 M
Alzheimer's Disease	6,000,000 <sup>28</sup>	500,000 <sup>28</sup>	○ ○	○		\$1.5 B - \$11.3 B
Severe Major Depressive Disorder	1,000,000 <sup>10</sup>	20,000 <sup>10,29</sup>		○		\$90 M - \$150 M
Stroke Rehabilitation	2,000,000 <sup>30</sup>	610,000 <sup>30</sup>		○		\$1.83 B - \$5.49 B
Frontotemporal Dementia	60,000 <sup>31</sup>	12,000 <sup>31</sup>	○			\$54 M - \$270 M
						<b>\$4.2 B - \$20.8 B</b>

ESTIMATED LAUNCH SEQUENCE

- Commercial U.S & EU ClearPoint procedures today
- Active clinical trial
- Pre-clinical study/testing



ClearPoint Neuro Navigation Capital, Robotics & Disposables  
 Cannulas, Pumps | MER Probes | Laser Cath., Biopsy  
 Access Technologies, Clinical Services, Digital Health

\*Citations & footnotes on next slide

---



















## ClearPoint Neuro Market Opportunity – United States

### Citations & Footnotes

1. "Parkinson's Disease Statistics," Parkinson's News Today, <https://parkinsonsnewstoday.com/parkinsons-disease-statistics/#:~:text=An%20estimated%20seven%20to%2010,who%20are%2080%20and%20older>
2. Neuron Therapeutics. (2021 November 4). *Neuron Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients* [Press release] [https://www.neurontherapeutics.com/wp-content/uploads/2021/11/2021\\_11\\_01\\_-INDClearance\\_FINALVersion.pdf](https://www.neurontherapeutics.com/wp-content/uploads/2021/11/2021_11_01_-INDClearance_FINALVersion.pdf)
3. Asadi-Pooya AA, Stewart GR, Abrams DJ, Sharan A. Prevalence and Incidence of Drug-Resistant Mesial Temporal Lobe Epilepsy in the United States. *World Neurosurg.* 2017;99:662-666.
4. Zesiewicz TA, Chari A, Jahan I, Miller AM, Sullivan KL. Overview of essential tremor. *Neuropsychiatr Dis Treat.* 2010;6:401-408. Published 2010 Sep 7.
5. Diaz NL, Louis ED. Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists. *Parkinsonism Relat Disord.* 2010;16(9):604-607.
6. Includes: Glioblastoma, Diffuse Intrinsic Pontine Glioma and deep small eloquent brain tumors.
7. "Glioblastoma Multiforme," American Association of Neurological Surgeons, <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Glioblastoma-Multiforme>
8. "About DIPG/DMG," DIPG/DMG Registry, <https://dipgregistry.org/patients-families/about-dipg-dmg/>
9. Medtronic Clinical Summary – Reclaim DBS for Chronic Extreme OCD M947128A001.
10. Mantovani A, Lisanby SH. Brain stimulation in the treatment of anxiety disorders. In: Simpson HB, Neria Y, Lewis-Fernández R, Schneier F, eds. *Anxiety Disorders: Theory, Research and Clinical Perspectives*. Cambridge: Cambridge University Press; 2010:323-335.
11. <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Dystonia>
12. Medtronic DBS™ Therapy for Dystonia - Clinical Summary 2015.
13. Includes: AADC deficiency, Friedreich's ataxia, Angelman syndrome, multiple system atrophy, metachromatic leukodystrophy, and spinocerebellar ataxia type 3.
14. "Multiple System Atrophy," Medscape, <https://emedicine.medscape.com/article/1154583-overview#a6>
15. PTC Therapeutics November 30, 2021 Corporate Presentation, <https://ir.ptcbio.com/static-files/0fd5d54f-55b8-416b-8006-4eb4c0d82f45>
16. "Spinocerebellar ataxia type 3," Orphanet, [https://www.orpha.net/consor/cgi-bin/OC\\_Exp.php?lng=EN&Expert=98757](https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=98757)
17. Lysogene Corporate Presentation at 38th Annual J.P. Morgan Healthcare Conference on Jan 13, 2020, [http://www.lysogene.com/wp-content/uploads/2020/01/jpm-2020-corporate-presentation\\_final.pdf](http://www.lysogene.com/wp-content/uploads/2020/01/jpm-2020-corporate-presentation_final.pdf)
18. "Metachromatic Leukodystrophy," National Organization of Rare Disorders, <https://rarediseases.org/rare-diseases/metachromatic-leukodystrophy/>
19. "Aromatic L' Amino Acid Decarboxylase Deficiency," National Organization for Rare Disorders, <https://rarediseases.org/rare-diseases/aromatic-l-amino-acid-decarboxylase-deficiency/>
20. Puckett Y, Mallorga-Hernández A, Montañó AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. *Orphanet J Rare Dis.* 2021;16(1):241. Published 2021 May 29.
21. Includes: stroke, spinal cord injury, multiple sclerosis, cerebral palsy, other (traumatic brain injury, complications from surgery, amyotrophic lateral sclerosis, neurofibromatosis, Chiari malformation, syringomyelia, postpolio syndrome, spinal muscular atrophy, Friedreich's ataxia, transverse myelitis, and spina bifida).
22. Armour BS, Courtney-Long EA, Fox MH, Fredine H, Cahill A. Prevalence and Causes of Paralysis-United States, 2013. *Am J Public Health.* 2016;106(10):1855-1857.
23. Wyndaele M, Wyndaele JJ. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?. *Spinal Cord.* 2006;44(9):523-529.
24. National Spinal Cord Injury Statistical Center (NSCISC): 2020 Annual Report and 2021 Facts and Figures. <https://www.nscisc.uab.edu/>
25. "Huntington's Disease," *Mov Disord.* 2019 Jun; 34(6): 858–865.
26. "Cochlear Implants," National Institute on Deafness and Other Communication Disorders, <https://www.nidcd.nih.gov/health/cochlear-implants>
27. "Cochlear Implant Surgery," Medscape, <https://emedicine.medscape.com/article/857242-overview>
28. "Alzheimer's Disease: Facts & Figures," Brightfocus Foundation, <https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures>
29. Goodman WK, Alterman RL. Deep brain stimulation for intractable psychiatric disorders. *Annu Rev Med.* 2012;63:511-524.
30. "Stroke Facts," Center for Disease Control and Prevention, <https://www.cdc.gov/stroke/facts.htm>
31. Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. *Int Rev Psychiatry.* 2013;25(2):130-137.

# Innovation Pipeline

## ClearPoint Neuro is Dedicated to Innovation in the Neuro Space

	First Use in 2022	Expected First Clinical Use by 2025*
<b>Functional Navigation &amp; Therapy</b>	 <p>ClearPoint Neuro Navigation Software v. 2.1</p>	 <p>Brain Computer Interface Navigation</p>
	 <p>ClearPoint Maestro™ Brain Model</p>	 <p>Maestro Sub-Nuclei Brain Model</p>
	 <p>ClearPoint Prism™ Neuro Laser Therapy System</p>	 <p>Micro-Electric Recording System (MER)</p>
		 <p>CT Based Navigation w/ Maestro Brain Model</p>
		 <p>MR Safe and "Smart" Biopsy Needles</p>
<b>Biologics &amp; Drug Delivery, Access Technologies</b>	 <p>Expanded Pre-Clinical Development Services for Pharma</p>	 <p>ClearPoint Maestro™ Infusion Modeling App*</p>
	 <p>ClearPoint Orchestra™ Pre-Clinical Head Fixation Frame</p>	 <p>ClearPoint Orchestra™ Head Fixation Frame</p>
	 <p>Operating Room Drill</p>	 <p>MRI Suite Safe Drill</p>
		 <p>Flexible, Chronic Drug Delivery Infusion Catheters</p>
		 <p>ClearPoint Maestro™ Infusion Targeting App</p>
		 <p>Spinal Infusion Catheter</p>
		 <p>MyClearPoint™ Patient Digital Health App</p>

New Global Showcase Site

# ClearPoint Global Training & Innovation Center – Solana Beach, CA

- Simulated training experience for surgeons and staff to perform mock procedures and provide development pipeline feedback
- Showcase new technologies to Pharmaceutical and BCI partners
- Home for Clinical Specialists to support cases remotely without travel



# 4 Pillar Growth Strategy by 2025

Target Indications of > 1,000,000 Patients Diagnosed Each Year  
Potential Total Addressable Market for CLPT of \$12B+



# CLPT Capabilities Executive Summary



**Unique platform technology**  
enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders



**Pipeline of new revenue streams**  
from product improvements, biologic and drug delivery partnerships and services, standalone therapy products, and Brain Computer Interface Navigation



**Expandable Platform**  
with realizable synergies beyond the MRI and into the operating room and radiology suite



**Large, growing installed base**  
in 65+ of 500+ leading Neurosurgery and research centers worldwide



**Total potential addressable market**  
> \$12B for our products, pipeline and partnerships



**A growing and passionate team**  
of embedded scientists and specialists



© 2023 CLEARPOINT NEURO





CLEARPOINT®  
NEURO



